Opendata, web and dolomites

CONVINCE SIGNED

The Comparison of High-Dose Heamodiafiltration (HDF) versus Haemodialyse

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CONVINCE project word cloud

Explore the words cloud of the CONVINCE project. It provides you a very rough idea of what is the project "CONVINCE" about.

annual    versus    15    diseases    consequence    communicable    intervention    became    put    below    patients    money    accepted    question    treatment    disease    decade    guideline    strategies    supports    kidney    ranks    lacking    fatal    prospective    medicine    dose    cardiovascular    unmet    stable    severe    effort    hospitalisation    dialysis    answer    everyday    definite    stage    haemodialysis    gives    hemodialysis    land    vast    standard    haemodiafiltration    regenerative    10    randomized    accumulated    majority    idea    experimental    function    paper    clinical    small    burden    publish    endpoints    effecticvely    utility    life    care    conventional    urgently    waste    progression    end    improvement    society    proof    infections    rates    mark    alternative    removes    transplantation    quality    trial    therapy    prevent    risks    mortality    superiority    replacement    haemodialfiltration    regulatory    medical    patient    substantial    normal    chronic   

Project "CONVINCE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.convincetrial.eu
 Total cost 6˙865˙425 €
 EC max contribution 6˙440˙488 € (94%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 573˙062.00
2    JULIUS CLINICAL RESEARCH BV NL (ZEIST) participant 2˙256˙001.00
3    FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH DE (BAD HOMBURG) participant 850˙675.00
4    DIAVERUM SWEDEN AB SE (LUND) participant 701˙550.00
5    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 555˙127.00
6    B.Braun Avitum AG DE (MELSUNGEN) participant 510˙537.00
7    ROYAL FREE LONDON NHS FOUNDATION TRUST UK (LONDON) participant 413˙593.00
8    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 361˙190.00
9    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 209˙063.00
10    UNIVERSITA DEGLI STUDI DI BARI ALDO MORO IT (BARI) participant 9˙687.00

Map

 Project objective

End stage kidney disease ranks among the most severe chronic non-communicable diseases with an unmet medical need, given the high (between 10 and 15%) and stable annual mortality rates. Kidney replacement therapy is necessary when kidney function is below 10% of the normal value. Much effort is put into developing strategies to prevent chronic kidney disease progression. Regenerative medicine still is in the experimental phase and kidney transplantation is only available for a small number of patients. Indeed, the everyday reality is the growing number of dialysis patients. Haemodialysis treatment is the current standard of care for the vast majority of patients with end stage kidney disease. It is a substantial burden to the patient and for society. Haemodialysis treatment is associated with high risks for fatal and non-fatal cardiovascular disease, for infections, hospitalisation and low quality of life. Improvement in the currently available standard is urgently needed.

Over the past decade an alternative for haemodialysis became available, i.e. haemodiafiltration. Both are accepted by regulatory authorities. Haemodiafiltration removes waste products that are accumulated due to kidney failure, more effecticvely than standard hemodialysis. Present evidence supports the idea of superiority of haemodialfiltration compared to standard haemodialysis. However, definite proof is lacking and as a consequence haemodiafiltration is not yet widely applied.

This consortium aims to determine the best possible dialysis treatment by comparing the conventional guideline based haemodialysis treatment versus high-dose haemodiafiltration by carrying out a prospective randomized controlled clinical trial addressing clinical endpoints, quality of life and a cost-utility analysis. The study will deliver an answer on the question which intervention gives the best value for money. Therefore, it will be considered a “land mark” study, allowing to publish an “end of discussion” paper

 Deliverables

List of deliverables.
Project plan with general description of RCT, also including inclusion and exclusion criteria Documents, reports 2020-04-17 18:13:36
Project logo and website Websites, patent fillings, videos etc. 2020-04-07 22:44:45
Rationale and study paper Documents, reports 2020-04-07 22:44:45

Take a look to the deliverables list in detail:  detailed list of CONVINCE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONVINCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONVINCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More